Loading clinical trials...
Loading clinical trials...
The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Psychiatric University Hospital Zurich
Zurich, Switzerland
Start Date
January 13, 2025
Primary Completion Date
September 30, 2026
Completion Date
September 30, 2026
Last Updated
January 16, 2025
85
ESTIMATED participants
50% N2O plus 50% O2
DRUG
Oxygen (O2)
DRUG
Lead Sponsor
University of Zurich
NCT07025720
NCT07432438
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions